The difference of 11.7 months in median overall survival between treatment with 177Lu-Dotatate and high-dose long-acting octreotide alone may be regarded clinically important, despite the fact that the final overall survival did not reach statistical significance [ 73 , 203 ].
← all excerpts
A Comprehensive Review on Neuroendocrine Neoplasms: Presentation, Pathophysiology and Management.
1
—
—